April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Quantitative Optical Coherence Tomography Findings Fom the ABC Trial in Various Subtypes of Neovascular Age-Related Macular Degeneration
C. A. Briceno; P. A. Keane; P. J. Patel; F. K. Chen; Y. L. Ouyang; F. Ikeji; A. C. Walsh; A. Tufail; S. R. Sadda
Author Affiliations & Notes
  • C. A. Briceno
    Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California
  • P. A. Keane
    Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California
  • P. J. Patel
    Clinical Trials Unit, Moorfields Eye Hospital, London, United Kingdom
  • F. K. Chen
    Clinical Trials Unit, Moorfields Eye Hospital, London, United Kingdom
  • Y. L. Ouyang
    Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California
  • F. Ikeji
    Clinical Trials Unit, Moorfields Eye Hospital, London, United Kingdom
  • A. C. Walsh
    Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California
  • A. Tufail
    Clinical Trials Unit, Moorfields Eye Hospital, London, United Kingdom
  • S. R. Sadda
    Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California
  • Footnotes
    Commercial Relationships  C.A. Briceno, None; P.A. Keane, None; P.J. Patel, None; F.K. Chen, None; Y.L. Ouyang, None; F. Ikeji, None; A.C. Walsh, Member of the scientific advisory board for Heidelberg Engineering, E; Co-inventor of Doheny intellectual property related to optical coherence tomography that has been licensed by Topcon Medical Systems, P; A. Tufail, None; S.R. Sadda, Member of the scientific advisory board for Heidelberg Engineering, E; Co-inventor of Doheny intellectual property related to optical coherence tomography that has been licensed by Topcon Medical Systems, P.
  • Footnotes
    Support  Supported in part by NIH Grant EY03040 and NEI Grant R01 EY014375
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5247. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Quantitative Optical Coherence Tomography Findings Fom the ABC Trial in Various Subtypes of Neovascular Age-Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      C. A. Briceno, P. A. Keane, P. J. Patel, F. K. Chen, Y. L. Ouyang, F. Ikeji, A. C. Walsh, A. Tufail, S. R. Sadda; Quantitative Optical Coherence Tomography Findings Fom the ABC Trial in Various Subtypes of Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5247.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To compare the volume of retinal morphological features, quantified using optical coherence tomography (OCT), with fluorescein angiographic classification in patients enrolled in the Avastin (Bevacizumab) for Choroidal Neovascularization (ABC) Trial.

Methods: : 122 cases of previously untreated, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) were evaluated from the ABC Trial. CNV lesions were classified by investigators at enrollment as classic with no occult, predominantly classic, minimally classic, or as occult with no classic. Corresponding Stratus OCT image sets were analyzed by certified graders at the Doheny Image Reading Center using custom software, entitled "OCTOR". Thickness/volume measurements for the neurosensory retina, subretinal fluid (SRF), pigment epithelium detachment (PED), and subretinal tissue (SRT), were calculated and compared with angiographic lesion classification.

Results: : The mean thickness of the neurosensory retina at the foveal center point was 269 ± 91 µm. Retinal thickness was greatest in lesions classified as classic with no occult (306 ± 105 µm) and least in minimally classic lesions (258 ± 64 µm). SRF was present at baseline in 104 (85%) eyes and had a total volume of 0.55 ± 1.16 mm3. SRF volume was greatest in classic with no occult lesions (0.72 ± 1.15 mm3), and least in minimally classic lesions (0.39 ± 0.48 mm3). PED was present at baseline in 104 (85%) eyes and had a total volume of 0.78 ± 0.92 mm3. PED volume was greatest in occult (0.91 ± 0.99 mm3) or minimally classic lesions (0.95 ± 0.99 mm3), and least in classic with no occult lesions (0.16 ± 0.38 mm3). SRT was present at baseline in 109 (89%) of eyes and had a total volume of 0.56 ± 0.61 mm3. SRT volume was greatest in classic with no occult lesions (1.09 ± 0.90 mm3), and least in occult with no classic lesions (0.30 ± 0.44 mm3).

Conclusions: : Quantitative OCT subanalysis allows for an improved understanding of the structural characteristics of angiographically defined CNV lesions. OCT plays a critical role in the diagnosis and treatment of patients with neovascular AMD - in the future, hybrid classifications of CNV, based on OCT and fluorescein angiographic parameters, may be of use in clinical trials of this disorder.

Clinical Trial: : www.ISRCTN.org 83325075

Keywords: age-related macular degeneration • imaging/image analysis: clinical • choroid: neovascularization 
© 2009, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept